GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 170 Note 61 : The spread of COVID-19 is having an unprecedented impact on people and economy. This has impacted our operations and results for the year ended March 31, 2022. The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade receivables, tangible assets, intangible assets and investments. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Company, as at the date of approval of these financial statements has used internal and external sources of information. The impact assessment of COVID-19 is a continuing process given the uncertainities and the Company will continue to closely monitor the developments. Note 62: Previous year figures have been regrouped / reclassified wherever necessary. Note 63: Approval of financial statements The financial statements were approved for issue by the Board of Directors on May 16, 2022. For and on behalf of the Board of Directors R. S. Karnad Chairperson DIN: 00008064 S. Venkatesh Managing Director DIN: 07263117 J. Chandy CFO & Whole-time Director DIN: 09530618 D. Sundaram Audit Committee Chairman DIN: 00016304 A. Nadkarni Company Secretary FCS 10460 Mumbai, May 16, 2022